ストックスクリーナーアプリを入手
2.00
1.74%
0.0342
前日終値:
$1.9658
開ける：
$1.94
24時間の取引高:
681
Relative Volume:
0.07
時価総額：
$12.73M
収益：
$105.38M
当期純損益:
$17.78M
株価収益率:
0.7491
EPS:
2.67
ネットキャッシュフロー:
$-50.48M
1週間 パフォーマンス:
+4.71%
1か月 パフォーマンス:
-13.04%
6か月 パフォーマンス:
-27.01%
1年 パフォーマンス:
-38.46%
1日の値動き範囲:
$1.94
$1.97
1週間の範囲:
$1.46
$2.07
52週間の値動き範囲:
$1.46
$4.10
Mei Pharma Inc Stock (MEIP) Company Profile
MEIP を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
MEIP
Mei Pharma Inc
|
1.97 | 12.73M | 105.38M | 17.78M | -50.48M | 2.67 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.09 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
559.01 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
594.73 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
229.77 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
229.84 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Mei Pharma Inc Stock (MEIP) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2024-07-23 | ダウングレード | Laidlaw | Buy → Hold |
| 2022-03-25 | ダウングレード | Jefferies | Buy → Hold |
| 2022-03-25 | ダウングレード | Stifel | Buy → Hold |
| 2022-03-25 | ダウングレード | Wells Fargo | Overweight → Equal Weight |
| 2022-02-03 | 開始されました | Jefferies | Buy |
| 2020-09-22 | 開始されました | Alliance Global Partners | Buy |
| 2020-05-29 | 開始されました | SunTrust | Buy |
| 2018-12-20 | 開始されました | H.C. Wainwright | Buy |
| 2018-07-27 | アップグレード | Stifel | Hold → Buy |
| 2018-07-13 | 開始されました | SunTrust | Buy |
| 2016-04-18 | 繰り返されました | Wedbush | Neutral |
| 2015-03-23 | ダウングレード | ROTH Capital | Buy → Neutral |
| 2014-12-18 | 繰り返されました | ROTH Capital | Buy |
| 2014-10-16 | 繰り返されました | ROTH Capital | Buy |
| 2014-07-08 | 再開されました | Brean Capital | Buy |
| 2013-10-22 | 繰り返されました | Stifel | Buy |
| 2013-04-15 | 開始されました | Stifel | Buy |
すべてを表示
Mei Pharma Inc (MEIP) 最新ニュース
MEI Pharma (NASDAQ:MEIP) Stock Passes Below Two Hundred Day Moving Average – Here’s What Happened - Defense World
StockNews.com Initiates Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $1.83 amid market challenges - Investing.com
MEI Pharma stock hits 52-week low at $1.83 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma (NASDAQ:MEIP) Coverage Initiated at StockNews.com - Defense World
MEI PHARMA INC- The GF Score's 5 Key Aspects of Analysis - GuruFocus
Follicular Lymphoma Market to Reach New Heights in Growth - openPR.com
Follicular Lymphoma Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Roche, BeiGene, Kite Pharma, Incyte Corp, AstraZeneca, MEI Pharma, Novartis, Innovent Biologics, Regeneron - Barchart.com
Virtu Financial LLC Purchases Shares of 10,744 MEI Pharma, Inc. (NASDAQ:MEIP) - Defense World
MEI Pharma (NASDAQ:MEIP) Now Covered by Analysts at StockNews.com - The AM Reporter
StockNews.com Begins Coverage on MEI Pharma (NASDAQ:MEIP) - Defense World
MEI Pharma stock hits 52-week low at $2.27 amid market challenges - Investing.com Australia
MEI Pharma (NASDAQ:MEIP) Coverage Initiated by Analysts at StockNews.com - Defense World
MEI Pharma stock hits 52-week low at $2.28 amid market challenges - Investing.com Australia
MEI Pharma stock hits 52-week low at $2.28 amid market challenges By Investing.com - Investing.com South Africa
MEI Pharma, Inc. to Host Earnings Call - ACCESS Newswire
10 Cheap Chinese Stocks to Buy Now - Insider Monkey
11 Best Undervalued Stocks to Invest in Now - Insider Monkey
The Polycythemia Vera Market Landscape Heats Up Amid Rising Competition Among Pharma Companies | DelveInsight - The Malaysian Reserve
C-COM Antenna Receives Eutelsat Type Approval - The Globe and Mail
Marginal Zone Lymphoma Clinical Trials and Studies: EMA, PDMA, FDA Approvals, Mechanism of Action, ROA, NDA, IND, and Companies - The Globe and Mail
Alarm.com (ALRM) Q4 Earnings: What To Expect - The Globe and Mail
Why Tight Corporate-U.S. Treasury Yield Spreads Signal Good News for Ag Markets Prices - The Globe and Mail
MEI Pharma Reports Increased Losses Amid Strategic Shift - TipRanks
MEI Pharma Reports Second Quarter Fiscal Year 2025 Cash Position - BioSpace
MEI Pharma Inc. (MEIP) reports earnings - Quartz
MEI Pharma, Inc. SEC 10-Q Report - TradingView
Geriatric Population And Unmet Healthcare Needs Fuel Growth In Acute Myeloid Leukemia Market: A Key Driver ... - WhaTech
Malt Lymphoma Pipeline 2024: Detailed Clinical Trials - openPR
Collegium Pharmaceutical, Inc. (NASDAQ:COLL) Receives $43.60 Average Target Price from Analysts - Defense World
No Headlines, No Problem: Why Technical Analysis Still Moves Stocks - The Globe and Mail
Layoff Tracker: Viracta, X4 and BMS Detail Current, Upcoming Cuts - BioSpace
Protein Bar Launch in Convenience Channel, Sending Shares of this MicroCap Higher - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Earns Buy Rating from Analysts at StockNews.com - Defense World
3 Easy Ways to Build Up Your Portfolio in 2025 - The Globe and Mail
Scientist pleads guilty to stealing trade secrets for Chinese pharma company - Fox28 Savannah
Kimberly-Clark: A Regal Opportunity in This Dividend King - The Globe and Mail
ROSEN, A LEADING LAW FIRM, Encourages Infinity Pharmaceuticals, - GuruFocus.com
Will PepsiCo Hike Its Dividend Soon?Looks LikelyValue Investors Love the Stock - The Globe and Mail
MEI Pharma (NASDAQ:MEIP) Now Covered by StockNews.com - Defense World
Assenagon Asset Management S.A. Buys 2,285 Shares of Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - Defense World
B-cell Non-hodgkin Lymphoma Clinical and Non-Clinical - openPR
Follicular Lymphoma Market Expected to rise, 2034 | Epizyme|Eisai, Bayer Healthcare Pharmaceuticals, Verastem Oncology, Gilead Sciences, TG Therapeutics, Bristol-Myers-Squibb, Roche, Incyte Corp - The Globe and Mail
Mei Pharma Inc (MEIP) 財務データ
収益
当期純利益
現金流量
EPS
0.77%
0.11%
大文字化:
|
ボリューム (24 時間):